Bronchopulmonary Dysplasia Market

Market Overview:

The 7 major bronchopulmonary dysplasia markets reached a value of US$ 269.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 445.6 Million by 2034, exhibiting a growth rate (CAGR) of 4.68% during 2024-2034.

The bronchopulmonary dysplasia market has been comprehensively analyzed in IMARC's new report titled "Bronchopulmonary Dysplasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bronchopulmonary dysplasia (BPD) refers to a chronic lung disease that primarily affects premature infants who require oxygen therapy and mechanical ventilation for acute respiratory distress syndrome or other neonatal respiratory problems. It is characterized by the abnormal development of lung tissue, inflammation, and scarring, which can lead to chronic respiratory symptoms, including wheezing, coughing, difficulty in breathing, etc. The severity of BPD can vary widely, with some infants experiencing mild indications that improve over time, while others require ongoing medical treatment and may develop long-term complications such as pulmonary hypertension, developmental delay, and growth impairment. The diagnosis of the ailment is typically made based on the infant's medical history, physical exam, and diagnostic tests. Several laboratory investigations are performed, including a chest X-ray, blood gas analysis, pulmonary function tests, and echocardiography to evaluate lung function, oxygen levels, and blood flow. In many cases, a lung biopsy may be necessary to confirm the diagnosis and rule out other respiratory conditions.

The increasing cases of lung injury and inflammation caused by several risk factors, including mechanical ventilation, oxygen toxicity, infections like pneumonia and sepsis, etc., are primarily driving the bronchopulmonary dysplasia market. Furthermore, the inflating application of bronchodilators, such as beta-agonists and anticholinergics, for relieving breathing difficulties in infants with BPD is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of diuretics, since they reduce fluid buildup in the lungs, which can help improve breathing and lower the risk of complications like pneumonia, is creating a positive outlook for the market. Moreover, the growing awareness regarding the long-term effects of BPD on infants has led to an increased interest in the development of new therapies and better management strategies. This, in turn, is also propelling the market growth. Additionally, the escalating demand for non-invasive ventilation, such as nasal continuous positive airway pressure (nCPAP), on account of its numerous associated benefits, including improved oxygenation and reduced need for invasive mechanical ventilation, is expected to drive the bronchopulmonary dysplasia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the bronchopulmonary dysplasia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bronchopulmonary dysplasia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bronchopulmonary dysplasia market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the bronchopulmonary dysplasia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the bronchopulmonary dysplasia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current bronchopulmonary dysplasia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the bronchopulmonary dysplasia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the bronchopulmonary dysplasia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the bronchopulmonary dysplasia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of bronchopulmonary dysplasia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of bronchopulmonary dysplasia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of bronchopulmonary dysplasia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with bronchopulmonary dysplasia across the seven major markets?
• What is the size of the bronchopulmonary dysplasia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of bronchopulmonary dysplasia?
• What will be the growth rate of patients across the seven major markets?
   

Genital warts: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for bronchopulmonary dysplasia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bronchopulmonary dysplasia market?
• What are the key regulatory events related to the bronchopulmonary dysplasia market?
• What is the structure of clinical trial landscape by status related to the bronchopulmonary dysplasia market?
• What is the structure of clinical trial landscape by phase related to the bronchopulmonary dysplasia market?
• What is the structure of clinical trial landscape by route of administration related to the bronchopulmonary dysplasia market?